Product Images Desvenlafaxine

This text describes the effects of hepatic and renal impairment, as well as age and gender, on the plasma concentrations of an unknown drug. The data suggests that renal impairment has a moderate effect on Cmax and a greater effect on AUC, with more severe impairment resulting in higher plasma concentrations. Hepatic impairment has a smaller effect, with moderate and severe impairment resulting in slightly higher Cmax and AUC values. The text includes population descriptions such as age and gender, as well as a footnote defining ESRD as end-stage renal disease.*

This is a pharmacokinetic data table showing changes in CYP3A4 inhibitors due to Ketoconazole. It includes the geometric mean ratio of the maximum concentration (Cmax) and area under the curve (AUC) of Ketoconazole with a confidence interval of 30%. The values in parentheses represent the upper and lower bounds of the confidence interval. The table also shows the change relative to the reference.*

This appears to be a graph showing the estimated proportion of patients with relapse over time using Desvenlafaxine Extended-Release Tablets 50mg versus placebo. The X-axis indicates the time to relapse in days, while the Y-axis shows the estimated percentage of patients experiencing relapse. The graph suggests that Desvenlafaxine may be more effective than placebo in preventing relapse.*

This appears to be a graph showing the estimated proportion of patients with relapse over time for Desvenlafaxine Extended-Release Tablets compared to placebo. The x-axis shows time to relapse in days from randomization and the y-axis shows the percentage of patients with relapse. The graph shows a higher percentage of relapse with placebo compared to Desvenlafaxine. The values on the y-axis range from 20% to 50%.*